RegulatoryMay 13, 2026, 05:02 PM
IceCure Medical Gets 180-Day Nasdaq Extension for Bid Price Compliance
AI Summary
IceCure Medical Ltd. announced it has been granted an additional 180-day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The new deadline for the company to meet the rule is November 9, 2026. This extension follows an initial notification in November 2025, and IceCure Medical plans to cure the deficiency, potentially through a reverse share split, with no immediate impact on its Nasdaq listing.
Key Highlights
- IceCure Medical received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price rule.
- The new deadline for compliance is November 9, 2026.
- Nasdaq's initial notification of non-compliance was issued on November 12, 2025.
- The first 180-day compliance period ended on May 11, 2026.
- The company intends to cure the deficiency, potentially through a reverse share split.
- The closing bid price must be at least $1.00 for a minimum of 10 consecutive business days to regain compliance.
- The notification has no immediate effect on the listing or trading of IceCure Medical's ordinary shares.
Price Impact
More from ICCM